GUARDANT HEALTH Reports 25.7% Increase in Total Revenue for Q2 FY2023 at $137.2 Million
August 21, 2023
☀️Earnings Overview
GUARDANT HEALTH ($NASDAQ:GH) reported total revenue of USD 137.2 million for the second quarter of FY2023, a 25.7% increase compared to the same quarter of the previous year, on June 30 2023. However, net income decreased significantly to USD -72.8 million, compared to the -229.4 million reported in the same quarter of the previous year.
Analysis
GoodWhale can help us to analyze GUARDANT HEALTH’s fundamentals. According to GoodWhale’s Star Chart, GUARDANT HEALTH is classified as ‘cheetah’, a type of company with high revenue or earnings growth but considered less stable due to lower profitability. This suggests that the company is attractive to investors who are looking for high growth potential, but they should also be aware of the risks that come with investing in less stable companies. GUARDANT HEALTH has a low health score of 2 out of 10, considering its cash flows and debt. This suggests that the company is less likely to pay off its debt and fund future operations. Furthermore, GoodWhale rating of GUARDANT HEALTH shows that it is strong in growth, medium in asset and weak in dividend and profitability. This means that investors should be aware of the risks of investing in GUARDANT HEALTH before doing so. They should consider the company’s financial situation and growth potential before deciding if this is a viable investment. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Guardant Health. More…
| Total Revenues | Net Income | Net Margin |
| 510.16 | -508.23 | -99.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Guardant Health. More…
| Operations | Investing | Financing |
| -337.37 | 28 | 366.01 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Guardant Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.84k | 1.55k | 2.49 |
Key Ratios Snapshot
Some of the financial key ratios for Guardant Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.6% | – | -98.8% |
| FCF Margin | ROE | ROA |
| -75.1% | -254.0% | -17.1% |
Peers
The competition in the market for cancer detection and treatment is heating up. Guardant Health Inc, a leading player in the field, is up against some stiff competition from the likes of Aclaris Therapeutics Inc, Inoviq Ltd, and Biomark Diagnostics Inc. All these companies are vying for a share of the pie in this rapidly growing market. While Guardant Health Inc has a strong product portfolio and a good track record, its competitors are not far behind and are also making inroads into this market. It remains to be seen who will emerge victorious in this battle.
– Aclaris Therapeutics Inc ($NASDAQ:ACRS)
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of dermatological and immuno-inflammatory diseases. The company’s lead product candidates include ATI-502 for the treatment of seborrheic keratosis, and ATI-501 for the treatment of vitiligo. Aclaris Therapeutics Inc has a market cap of 1.11B as of 2022, a Return on Equity of -25.42%.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd is a publicly traded company with a market capitalization of 50.61M as of 2022. The company’s return on equity (ROE) is -13.68%. Inoviq Ltd is engaged in the development and commercialization of innovative drugs and therapies. The company’s products are designed to improve the lives of patients with serious medical conditions. Inoviq’s products are available in more than 60 countries worldwide.
– Biomark Diagnostics Inc ($OTCPK:BMKDF)
Biomark Diagnostics Inc is a company that provides diagnostic testing services. The company has a market capitalization of 10.88 million as of 2022 and a return on equity of 179.57%. The company’s diagnostic testing services include tests for cancer, cardiovascular disease, and infectious diseases. Biomark Diagnostics Inc is headquartered in the United States.
Summary
Investors may be cautiously optimistic about investing in Guardant Health following their second quarter results of FY2023, with total revenue increasing by 25.7% year over year. Despite the significant increase in revenue, net income decreased drastically from the same period last year, resulting in a net loss of USD -72.8 million. Nevertheless, investors may consider the potential for future growth and focus on the positive revenue results moving forward.
Related Posts
Recent Posts
